Littérature scientifique sur le sujet « Résistance aux antibiotiques – Lutte contre »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Résistance aux antibiotiques – Lutte contre ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Résistance aux antibiotiques – Lutte contre"
Abdoulaye, O., et Et Al. « Résistance des Résistance des bactéries aux antibiotiques : états des lieux au Niger en 2022rbactéries aux antibiotiques : états des lieux au Niger en 2022 ». Revue Malienne d'Infectiologie et de Microbiologie 18, no 2 (30 décembre 2023) : 70–81. http://dx.doi.org/10.53597/remim.v18i2.2742.
Texte intégralCarlet, Jean. « Une lutte globale contre la résistance bactérienne aux antibiotiques ». Soins 60, no 797 (juillet 2015) : 44. http://dx.doi.org/10.1016/j.soin.2015.04.033.
Texte intégralLemaoui, C. E., H. Layaida, A. Badi et N. Foudi. « Stratégies actuelles de lutte contre la résistance aux antibiotiques ». Journal des Anti-infectieux 19, no 1 (mars 2017) : 12–19. http://dx.doi.org/10.1016/j.antinf.2017.01.003.
Texte intégralOvetchkine, P. « La lutte contre la résistance aux antibiotiques passe aussi par l'information aux parents ». Archives de Pédiatrie 6, no 3 (mars 1999) : 321–23. http://dx.doi.org/10.1016/s0929-693x(99)80274-7.
Texte intégralIllouz, Morgane, Matthéo Alcaraz, Françoise Roquet-Banères et Laurent Kremer. « Mycobacterium abscessus, un modèle de résistance aux différentes classes d’antibiotiques ». médecine/sciences 37, no 11 (novembre 2021) : 993–1001. http://dx.doi.org/10.1051/medsci/2021164.
Texte intégralMion, Sonia, Benjamin Rémy, Laure Plener, Éric Chabrière et David Daudé. « Quorum sensing et quorum quenching : Comment bloquer la communication des bactéries pour inhiber leur virulence ? » médecine/sciences 35, no 1 (janvier 2019) : 31–38. http://dx.doi.org/10.1051/medsci/2018310.
Texte intégralBah, Mariama, Namory Keita, Mory Sangare, Aboubacar Hady Toure, Mamadou Alpha Balde, Raphael Dore et Mamadou Cellou Balde. « Détection par des techniques modernes de Shigella spp dans différentes sources d’eaux de la zone péri-urbaine de Kindia (Basse Guinée), République de Guinée ». International Journal of Biological and Chemical Sciences 16, no 6 (8 mars 2023) : 2585–94. http://dx.doi.org/10.4314/ijbcs.v16i6.10.
Texte intégralImbeault, Sandra, Serge Parent, Jean-François Blais, Michel Lagacé et Carl Uhland. « Utilisation de bactériophages pour contrôler les populations de Aeromonas salmonicida résistantes aux antibiotiques ». Revue des sciences de l'eau 19, no 4 (17 janvier 2007) : 275–82. http://dx.doi.org/10.7202/014415ar.
Texte intégralOtaigbe, I. I., P. O. Oshun et O. O. Oduyebo. « Pattern of inappropriate antibiotic use among patients in the medical wards of a tertiary hospital in southwest Nigeria ». African Journal of Clinical and Experimental Microbiology 25, no 1 (16 janvier 2024) : 86–94. http://dx.doi.org/10.4314/ajcem.v25i1.10.
Texte intégralNwajiobi-Princewill, P., N. Medugu, M. Gobel, A. Aigbe, A. Versporten, I. Pauwels, H. Goossens et K. C. Iregbu. « Using longitudinal antibiotic point prevalence survey (PPS) to drive antimicrobial stewardship programmes in a Nigerian tertiary hospital ». African Journal of Clinical and Experimental Microbiology 22, no 2 (8 avril 2021) : 284–89. http://dx.doi.org/10.4314/ajcem.v22i2.22.
Texte intégralThèses sur le sujet "Résistance aux antibiotiques – Lutte contre"
Sevaille, Laurent. « Inhibition de métallo-B-lactamases (MBLs) pour lutter contre la résistance bactérienne aux antibiotiques ». Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTS136.
Texte intégralThe spread of multiresistant Gram negative bacteria is a growing threat to public health and the risk of return to the pre-antibiotic era is real. Among existing resistance modes, the production of metallo-B-lactamases (MBLs) responsible of the inactivation of B-lactams, the most used family of antibiotics, represents a therapeutical challenge.This manuscript describes the synthesis, characterization and biological evaluation of compounds built on a 2,4-dihydro-3H-1,2,4-triazole-3-thione scaffold substituted on two positions. Based on previous in silico screening and crystallographic studies, which identified this structure as a good candidate for MBLs inhibition, several series have been developed to found new inhibitors that could potentially be amenable to clinical development.First, 1,2,4-triazole-3-thione compounds substituted at position 5 have been prepared following classical pathways. Then, several series have been developed where the structural and functional diversity was introduced at position 4. Compounds have been tested on representative MBLs of the three sub-classes and the most interesting ones on recombinant resistant bacteria.To perform a rapid screening of compounds in the laboratory, a method of medium throughput screening inhibition tests on five MBLs performed in 96-wells plate has also been developed and validated during this study with the help of our collaborators specialists of MBLs
Chevrot, Romain. « Recherche de composés inhibiteurs de la croissance et du quorum sensing de Pseudomonas aeruginosa ». La Rochelle, 2007. http://www.theses.fr/2007LAROS215.
Texte intégralPseudomonas aeruginosa (Pa) is an ubiquitary, opportunist and pathogenic bacteria, which is more and more resistant to antibiotics. We have researched new molecules from chemical syntheses or bacterial origin, inhibiting the growth or the quorum sensing (QS) of Pa. The synthesized molecules tested have not presented any anti-Pa activity but have allowed the development of protocols used to study the inhibitory activities from bacterial origin. The anti-Pa bacteria have been researched in niches colonized by Pa : poultry intestines, “sanitary” and sputum from cystic fibrosis patients. The study of an anaerobic strain already isolated from duck intestine and presenting an anti-Pa activity has been performed. It belongs to a new species and has been named Megamonas rupella. Its activity is mainly due to the production of propionate and acetate with the possible contribution of a peptidic compound. Two strains related to Paenibacillus alvei inhibiting the growth of Pa and other pathogenic bacteria have been isolated from “sanitary” and pulmonary niches. It is the first time that such an activity is described for this species and that an anti-Pa strain other than a pyocinogenic Pa is isolated from the pulmonary niche. The P. Alvei strains present distinct antimicrobial spectra. In minimum media, one of the P. Alvei produces polymyxin B1 and other antimicrobial peptides. The other strain could produce mainly a fusaricidin like compound. The strains isolated during this work could be used for biocontrol or industrial production of new anti-Pa compounds
Compagne, Nina. « Développement d'inhibiteurs des pompes d'efflux des bactéries Gram négatives pour lutter contre la résistance aux antibiotiques ». Electronic Thesis or Diss., Université de Lille (2022-....), 2023. http://www.theses.fr/2023ULILS032.
Texte intégralThe discovery of antibiotics in the 20th century allowed to treat a number of previously fatal bacterial infectious diseases. However, this therapeutic progress was followed by a massive, repeated and inappropriate use of antibiotics, leading to the rise of antimicrobial resistance. This phenomenon is alarming, with an estimated 4.95 million deaths associated with antibiotic resistance in 2019. One of the resistance mechanisms developed by Enterobacterales and overall Gram-negative bacteria is the (over)expression of efflux pumps. These bacterial pumps are able to extrude several classes of antibiotics, thereby reducing their intrabacterial concentration and rendering them ineffective. One strategy being considered to circumvent this phenomenon is the development of efflux pump inhibitors which, in combination with an antibiotic, could offer a new therapeutic alternative to treat resistant bacterial infections.AcrAB-TolC is an efflux pump of the RND superfamily found in Enterobacterales such as Escherichia coli and Klebsiella pneumoniae. In order to identify inhibitors of this pump, a chemical library of 1280 fragments was screened on E. coli in combination with a model antibiotic substrate of this pump, leading to the selection of a hit compound belonging to the pyridylpiperazine family. This hit has no intrinsic antibacterial activity, but is able to potentiate the activity of a range of antibiotics by direct inhibition of the AcrB protein. Initial studies of structure-activity relationships have allowed the identification of two chemical series, the quinoline/quinoxaline series and the pyridine series. Structural modifications around these three cores were carried out using a rational design based on the co-crystallographic structures obtained with AcrB. 80 compounds were therefore synthesised in order to identify more potent analogues and establish new structure-activity relationships. In particular, the introduction of different substituents with an amine function allowed to create new interactions with acidic residues in the AcrB binding pocket. The physicochemical and in vitro pharmacokinetic parameters of the most promising compounds were then measured, leading to the selection of one compound for a pharmacokinetic study in mice. In order to enrich the chemical diversity of substituents introduced on the quinoline and pyridine rings, a chemical library of 672 triazoles was synthesised via a copper-catalysed cycloaddition reaction. The aim was to increase the potency of the compounds by creating new interactions with AcrB while reducing the cytotoxicity and intrinsic antibacterial activity of the compounds. This led to the identification of new compounds with promising activities, which will soon be resynthesised in order to characterise their biological effect and measure their ADME properties
Lôme, Vincent. « Des agents chimiosensibilisants pour lutter contre la résistance aux antibiotiques chez les bactéries Gram-négatif : criblage et caractérisation ». Thesis, Aix-Marseille, 2017. http://www.theses.fr/2017AIXM0063.
Texte intégralGram-negative bacteria are naturally resistant to many classes of antibiotics thanks to their ability to control the accumulation of drugs. Decreasing membrane barrier permeability and producing efflux pumps that expel drugs outside bacteria, represent the prevalent mechanisms of this resistance. One of the most promising solutions consists in restoring antibiotic activity by targeting such barriers to accumulation, with chemosensitizers.The purpose of my PhD was to better understand the inhibition of resistance that opposes the accumulation of antibiotics in Gram-negative bacteria.In the first stage of the study, the activity of various synthetic chemosensitizers has been characterized. Three compounds were identified to significantly increase the synergistic activity with antibiotics, that was previously observed with geraniol. These derivatives showed an efflux pump inhibition or an outer membrane permeabilization effect, that could be related to the observed synergy.In the second stage of the study, a screening method has been developed for the specific detection of chemosensitizers, while describing their mechanism of action.This work participated in proposing a patented therapeutic solution in the preclinical stage. This study has led to new tools to identify novel chemosensitizers, but also to better understand how to impair the barriers opposing the accumulation of antibiotics
Bailleul, Geoffrey. « Les défensines aviaires : nouveau moyen de lutte contre les entérobactéries pathogènes ». Thesis, Tours, 2016. http://www.theses.fr/2016TOUR3813.
Texte intégralLarge-scale use of antibiotics has leaded to the emergence of multi drug resistant bacterial strains, particularly in the genus Salmonella and Escherichia coli responsible for infectious diseases outbreaks. This constitutes a major veterinary and public health concern. Host defense peptides (HDPs) represent major effector molecules of the animal’s innate immune system. In birds, the main family of HDPs is composed of avian defensins whose two members (AvBD2 and AvBD7) isolated from chicken bone marrow exhibit large spectrum antibacterial activity. Thus, they both constitute potential candidate molecules as alternative to antibiotics. To demonstrate the therapeutic interest of AvBD2 and AvBD7, we have (1) proved their antibacterial efficiency in vitro towards clinical and multi drug resistant bacterial strains, (2) shown their functional and structural stability when facing major digestive proteases, (3) identified a novel antibacterial effect in infected macrophages, and finally (4) proved the therapeutic concept by reducing mortality and bacterial load after AvBD7 injection in a murine model of lethal salmonellosis
Majdi, Chaimae. « Lutte contre l'antibiorésistance : synthèse de dérivés de tryptamine et de juglone. Evaluation de leurs activités antibactériennes et d’adjuvants d’antibiotiques. Etudes de leur biodégradabilité ». Electronic Thesis or Diss., Nîmes, 2024. http://www.theses.fr/2024NIME0003.
Texte intégralGlobal health is threatened by antibiotic resistance at an unprecedented level today. As a result, the World Health Organization (WHO) now identified bacterial resistance as a "silent pandemic". As part of a global plan to combat antibiotic resistance, the WHO warned that infectious diseases will be the leading cause of death worldwide by 2050 unless action is taken now. A total of twelve families of antibiotic-resistant bacteria have been classified as critical, high, and medium priority organisms based on their resistance to antibiotics.This thesis project involved four studies to respond to this urgency. As part of the first one, five inhibitors of bacterial response regulators (RR, a protein involved in the bacterial resistance mechanism) were evaluated for their antibacterial and antibiotic adjuvant activity against bacteria classified as a critical priority by the WHO. It was observed that two of these five compounds demonstrated an excellent cefotaxime adjuvant activity by reducing its minimum inhibitory concentration by 256,000-fold and showing a remarkable synergistic effect against a clinical strain of Escherichia coli resistant to cefotaxime. The second study aims to design and synthesis of 64 tryptamine and naphthol derivatives and investigated them as antibiotic adjuvant agents against bacterial strains, which are also of critical priority. One tryptamine derivative from the carboxamide family showed the best activity, potentiating cefotaxime (267-fold) synergistically against Escherichia coli strain resistant to cefotaxime. The third study aimed to optimize the clinical use of colistin, the only last-resort treatment for life-threatening infections caused by enterobacteria. In this context, nineteen tryptamine derivatives from the urea family were synthesized and investigated as colistin adjuvants against clinical colistin-resistant strains. Among these derivatives, one compound showed particular potential as an adjuvant agent in the presence of colistin, with a 64-fold against the clinical colistin-resistant strain of Klebsiella pneumoniae. Finally, a fourth study involved the regioselective synthesis of sixteen aminojuglone derivatives under eco-friendly conditions using Michael addition in the presence of CeCl3·7H2O, and the evaluation of their biological activity against high-priority Gram-positive bacterial strains. Twelve compounds showed cloxacillin adjuvant effect with 4 to 66-fold on a clinical strain of methicillin-resistant S. aureus (MRSA). Only one of these twelve compounds complied with the "antibiotic adjuvant" concept, devoid from antibacterial activity while synergistically restoring the activity of cloxacillin (66-fold) against MRSA.All synthesized compounds possessing the best biological activity in this research work, are devoid of antibacterial activity while synergistically restoring antibiotic activity against resistant bacterial strains which is in line with the antibiotic adjuvant concept
Ntsogo, Enguene Véronique Yvette. « Nouvelle approche dans la lutte contre la résistance aux antibiotiques des bactéries colonisant les poumons des patients atteints de mucoviscidose : reconstitution d'une pompe d'efflux de Pseudomonas aeruginosa ». Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCB146/document.
Texte intégralMultidrug efflux systems are membrane transport proteins that are used to translocate a wide variety of drugs across the inner and the outer membranes of Gram-negative bacteria, leading to natural and acquired antimicrobial resistances.Most of the multidrug transporters of P. aeruginosa belong to the resistance-nodulation-cell division (RND) superfamily.They function as three-component assemblies made of an inner membrane transporter (RND), a periplasmic membrane fusion protein (MFP) and an outer membrane factor channel (OMF). Along with functional studies, many crystal structures of the individual components of the pump have been solved but the interactions underlying the complex assembly and the opening mechanism of the outer channel remain unclear. In this study, we investigated structural and functional insights of P. aeruginosa efflux pumps. We solved the crystal structure of the MexEF-OprN efflux pump outer membrane channel OprN mainly involved in fluoroquinolones resistance. Our new structure highlights the differences between P. aeruginosa and other Gram-negative bacteria OMFs that could explain their specific interaction with the cognate MFP partners. We also purified and characterized the inner membrane transporter MexY from the MexXY-OprM efflux pump, which is the major determinant of aminoglycosides resistance in P. aeruginosa. Besides, we solved the crystal structure of a mutatedform of the outer membrane channel OprM in order to understand its opening mechanism. We also investigated in vivo effect of the OprM mutants in antibiotics resistance by MIC measurements and tried to correlate with the observed structural modifications leading to the open state. Moreover, we set up a new in vitro test allowing the investigation of the assembly of the MexAB-OprM efflux pump. Our results showed the importance of MexA and its lipid anchor in promoting and stabilizing the complex assembly. In addition, as a side project with the group of Pr Plésiat (laboratoire de Bactériologie de Besançon), we built different structural models of AmpC mutants from overproducing clinical isolates,showing the possible conformational changes that lead to the resistance increase
Opatowski, Lulla. « Modélisation mathématique de la dynamique de diffusion de bactéries résistantes aux antibiotiques : application au pneumocoque ». Phd thesis, Université Pierre et Marie Curie - Paris VI, 2009. http://tel.archives-ouvertes.fr/tel-00814070.
Texte intégralMadi, Moussa Désiré. « Caractérisation de l’activité contre les bactéries à Gram-négatif, expression hétérologue et étude de la relation structure activité des bactériocines produites par Lacticaseibacillus paracasei CNCM I-5369 ». Electronic Thesis or Diss., Université de Lille (2018-2021), 2021. http://www.theses.fr/2021LILUR060.
Texte intégralThe excessive use of antibiotics has exacerbated the phenomenon of antibiotic resistance throughout the world. Today, the fight against antibiotic resistance has become a global public health priority. Indeed, every year, it is responsible for more than 700,000 deaths in the world and by 2050, it will cause more than 10 million deaths per year, if concrete actions are not implemented to curb the development of this phenomenon. In addition to the human losses, the financial cost of antibiotic resistance-related care could reach 100,000 billion dollars worldwide. To face this crisis, several innovative strategies, including the use of antimicrobial peptides (AMPs), have been proposed. In this perspective, bacteriocins, which are ribosomally APMs, could contribute to the therapeutic solution. Recently, the Lacticaseibacillus paracasei CNCM I-5369 strain has been particularly distinguished for its activity against Gram-negative pathogens. This activity is due to 5 new bacteriocins encoded by chromosomal genes orf010, orf012, orf023, orf030 and orf038. However, the activity is pH-dependent, i.e., it is exerted, only at a pH value ≤ 5. In the framework of this thesis, we first verified the expression of these genes during the growth of the bacteria, using the qPCR technique. Thus, we observed that these 5 genes were expressed after 24 h of growth, concomitantly with the appearance of antimicrobial activity indicating a possible link between gene expression and the production of the five bacteriocins. These 5 bacteriocins were expressed in a heterologous system in Escherichia coli Rosetta. It should be noted that only the bacteriocin encoded by orf030, called lacticaseicin 30, could be produced in large quantities, in contrast to the other bacteriocins which were produced but remain trapped in the insoluble fraction. In a second step, we investigated the relationship between the structure of lacticaseicin 30 and its activity against Gram-negative bacteria. Structural predictions suggested a 5-helix organization of lacticaseicin 30. The proportion of helix-α was greater at pH 5 than at pH 7. To identify the regions involved in the activity against Gram-negative bacteria, we produced lacticaseicin 30-derived peptides by a molecular biology approach. These derived peptides are obtained by reducing their sizes, or by inserting targeted mutations in different regions. Thus, we generated shorter forms of lacticaseicin 30, containing either its N-terminal region (amino acids 1 to 39), or the central and C-terminal regions (amino acids 40 to 111). Similarly, a derivative peptide containing only the first helix of the N-terminal region was also produced. Mutations introducing amino acid substitutions were introduced within the α-helices. With regard to their activities, these derived peptides localized antibacterial activity mainly in the N-terminal region, and requires at least two helix-αs. Furthermore, the activity of these peptide variants E32G, T33P, T52P, and D57G remained essentially the same, unlike to those of the variants E6G, T7P, D57G T52P, A74P, Y78S, Y93S, and A97P, which were significantly impaired. In the last part, we tested the activity of lacticaseicin 30 against a panel of Gram-negative clinical strains with colistin resistance. The results obtained highlighted a synergy between lacticase 30 and colistin and a significant reduction of the expression of the mcr-1 and mcr-9 genes, responsible for colistin resistance
Nicol, Marion. « Recherche d'outils thérapeutique innovants pour lutter contre la bactérie Acinetobacter baumannii ». Thesis, Normandie, 2017. http://www.theses.fr/2017NORMR132/document.
Texte intégralToday, Acinetobacter baumannii is one of the most problematic pathogens in the world. This bacterium is responsible for worldwide epidemic outbreaks associated with dramatic mortality rates. It possesses high capacities to evade the immune host system and to resist to numerous available antibacterial agents. A. baumannii is also able to persist into hospital environment due to high adhesion abilities which induce community development. This process is also associated to an enhanced survival rate. In Acinetobacter genus, community modes of lif can take two forms : biofilm and pellicle. In this study on the strain ATCC 17978, we tried to discriminate these two lifestyles by a large scale proteomic analysis. We have confirmed the presence of many common community markers (transporters, ion acquisition secretion systems, adhesins and pili) and highlighted systems specifically related to biofilm (pilus Fim, T2SS, T1SS / pump A1S_0535-38, LPS / LOS, capsular pattern) and pellicle communities. Furthermore the proteomic analysis of an avirulent A. baumannii strain, SDF, in biofilm allowed to highlight peculiar metabolic pathways, specific adhesion determinants but very few markers shared by ATCC 17978. This demonstrated the difficulty in developing a treatment directed against A. baumannii biofilm. Then, we tested different approaches to prevent and eradicate biofilms. The first one targeted the Quorum Sensing system (QS), an essential communication system for cell coordination. We have showed that monounsaturated fatty acids (palmitoleic acid and myristoleic acid), like virstatin prevent the community formation of A. baumannii by inhibiting the expression of the abaR regulator required for QS. In a second strategy, we have evaluated the antibacterial and antibiofilm activity of a new natural compound : the squalamine. We showed for the first time that if ciprofloxacin treatment was able to induce a dormancy population (persistent/VBNCs) in A. baumannii, squalamine was able to eradicate this population of dormant cells
Livres sur le sujet "Résistance aux antibiotiques – Lutte contre"
1925-, Pimentel David, dir. Encyclopedia of Pest Management. Boca Raton : CRC Press, 2007.
Trouver le texte intégral1925-, Pimentel David, dir. Encyclopedia of pest management. New York : Marcel Dekker, 2002.
Trouver le texte intégralBrooks, J. E. Development of a resistance index for Sitka spruce against the white pine weevil Pissodes strobi Peck. Victoria, B.C : Forestry Canada, 1992.
Trouver le texte intégralSharma, H. C. Biotechnological approaches for pest management and ecological sustainability. Boca Raton, FL : CRC Press, 2008.
Trouver le texte intégralChapitres de livres sur le sujet "Résistance aux antibiotiques – Lutte contre"
Bruttmann, Tal. « Chapitre 17 : La lutte contre le sauvetage durant l' « action brunner » en France ». Dans La résistance aux génocides, 291–303. Presses de Sciences Po, 2008. http://dx.doi.org/10.3917/scpo.andri.2008.01.0291.
Texte intégral